Review



cox1  (Huabio Inc)

 
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 86
      Buy from Supplier

    Structured Review

    Huabio Inc cox1
    A939572 inhibits OC differentiation by modulating arachidonic acid metabolism. (A) Integrated transcriptomic and metabolomic analysis. (B) Heatmap of PGD2‐related metabolites. i indicates inhibitor‐treated samples, NC indicates control samples. (C, D) GSEA of arachidonic acid and mineralization‐related metabolites. (E) PGD2 concentrations in cell measured by ELISA in each group ( n = 6). (F, G) Western blots showing HPGDS, <t>COX1</t> and COX2 protein levels in OCs treated with A939572. (H) Western blots showing c‐Fos and NFATc1 protein levels in BMDMs treated with varying concentrations of PGD2. (I) Changes in OC‐related markers following RANKL stimulation at different time points, with or without 0.625 μM PGD2 treatment. (J) RT‐qPCR analysis of OC‐related markers in response to different concentrations of PGD2. (K) TRAP staining and F‐actin immunofluorescence staining of OCs treated with or without PGD2; TRAP staining, Scale bars, 100 μm; F‐actin immunofluorescence staining, Scale bars, 100 μm. (L) Quantification of nuclei numbers of TRAP‐positive multinuclear cells ( n = 3). Data are presented as mean ± SD. NS, not significant ( p > 0.05), * p ≤ 0.05, ** p < 0.01, *** p < 0.001. Source numerical and statistical data are provided.
    Cox1, supplied by Huabio Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/cox1/product/Huabio Inc
    Average 86 stars, based on 1 article reviews
    cox1 - by Bioz Stars, 2026-05
    86/100 stars

    Images

    1) Product Images from "SCD1 Regulates Osteoclast Differentiation by Modulating Arachidonic Acid Metabolism and Mitochondrial Homeostasis"

    Article Title: SCD1 Regulates Osteoclast Differentiation by Modulating Arachidonic Acid Metabolism and Mitochondrial Homeostasis

    Journal: The FASEB Journal

    doi: 10.1096/fj.202600672R

    A939572 inhibits OC differentiation by modulating arachidonic acid metabolism. (A) Integrated transcriptomic and metabolomic analysis. (B) Heatmap of PGD2‐related metabolites. i indicates inhibitor‐treated samples, NC indicates control samples. (C, D) GSEA of arachidonic acid and mineralization‐related metabolites. (E) PGD2 concentrations in cell measured by ELISA in each group ( n = 6). (F, G) Western blots showing HPGDS, COX1 and COX2 protein levels in OCs treated with A939572. (H) Western blots showing c‐Fos and NFATc1 protein levels in BMDMs treated with varying concentrations of PGD2. (I) Changes in OC‐related markers following RANKL stimulation at different time points, with or without 0.625 μM PGD2 treatment. (J) RT‐qPCR analysis of OC‐related markers in response to different concentrations of PGD2. (K) TRAP staining and F‐actin immunofluorescence staining of OCs treated with or without PGD2; TRAP staining, Scale bars, 100 μm; F‐actin immunofluorescence staining, Scale bars, 100 μm. (L) Quantification of nuclei numbers of TRAP‐positive multinuclear cells ( n = 3). Data are presented as mean ± SD. NS, not significant ( p > 0.05), * p ≤ 0.05, ** p < 0.01, *** p < 0.001. Source numerical and statistical data are provided.
    Figure Legend Snippet: A939572 inhibits OC differentiation by modulating arachidonic acid metabolism. (A) Integrated transcriptomic and metabolomic analysis. (B) Heatmap of PGD2‐related metabolites. i indicates inhibitor‐treated samples, NC indicates control samples. (C, D) GSEA of arachidonic acid and mineralization‐related metabolites. (E) PGD2 concentrations in cell measured by ELISA in each group ( n = 6). (F, G) Western blots showing HPGDS, COX1 and COX2 protein levels in OCs treated with A939572. (H) Western blots showing c‐Fos and NFATc1 protein levels in BMDMs treated with varying concentrations of PGD2. (I) Changes in OC‐related markers following RANKL stimulation at different time points, with or without 0.625 μM PGD2 treatment. (J) RT‐qPCR analysis of OC‐related markers in response to different concentrations of PGD2. (K) TRAP staining and F‐actin immunofluorescence staining of OCs treated with or without PGD2; TRAP staining, Scale bars, 100 μm; F‐actin immunofluorescence staining, Scale bars, 100 μm. (L) Quantification of nuclei numbers of TRAP‐positive multinuclear cells ( n = 3). Data are presented as mean ± SD. NS, not significant ( p > 0.05), * p ≤ 0.05, ** p < 0.01, *** p < 0.001. Source numerical and statistical data are provided.

    Techniques Used: Metabolomic, Control, Enzyme-linked Immunosorbent Assay, Western Blot, Quantitative RT-PCR, Staining, Immunofluorescence



    Similar Products

    gene exp cox1 mm04225243 g1  (Thermo Fisher)
    95
    Thermo Fisher gene exp cox1 mm04225243 g1
    Gene Exp Cox1 Mm04225243 G1, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/gene exp cox1 mm04225243 g1/product/Thermo Fisher
    Average 95 stars, based on 1 article reviews
    gene exp cox1 mm04225243 g1 - by Bioz Stars, 2026-05
    95/100 stars
    		  Buy from Supplier
    cox1  (Huabio Inc)
    86
    Huabio Inc cox1
    A939572 inhibits OC differentiation by modulating arachidonic acid metabolism. (A) Integrated transcriptomic and metabolomic analysis. (B) Heatmap of PGD2‐related metabolites. i indicates inhibitor‐treated samples, NC indicates control samples. (C, D) GSEA of arachidonic acid and mineralization‐related metabolites. (E) PGD2 concentrations in cell measured by ELISA in each group ( n = 6). (F, G) Western blots showing HPGDS, <t>COX1</t> and COX2 protein levels in OCs treated with A939572. (H) Western blots showing c‐Fos and NFATc1 protein levels in BMDMs treated with varying concentrations of PGD2. (I) Changes in OC‐related markers following RANKL stimulation at different time points, with or without 0.625 μM PGD2 treatment. (J) RT‐qPCR analysis of OC‐related markers in response to different concentrations of PGD2. (K) TRAP staining and F‐actin immunofluorescence staining of OCs treated with or without PGD2; TRAP staining, Scale bars, 100 μm; F‐actin immunofluorescence staining, Scale bars, 100 μm. (L) Quantification of nuclei numbers of TRAP‐positive multinuclear cells ( n = 3). Data are presented as mean ± SD. NS, not significant ( p > 0.05), * p ≤ 0.05, ** p < 0.01, *** p < 0.001. Source numerical and statistical data are provided.
    Cox1, supplied by Huabio Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/cox1/product/Huabio Inc
    Average 86 stars, based on 1 article reviews
    cox1 - by Bioz Stars, 2026-05
    86/100 stars
    		  Buy from Supplier
    anti cox1 polyclonal antibody  (Cell Signaling Technology Inc)
    94
    Cell Signaling Technology Inc anti cox1 polyclonal antibody
    A939572 inhibits OC differentiation by modulating arachidonic acid metabolism. (A) Integrated transcriptomic and metabolomic analysis. (B) Heatmap of PGD2‐related metabolites. i indicates inhibitor‐treated samples, NC indicates control samples. (C, D) GSEA of arachidonic acid and mineralization‐related metabolites. (E) PGD2 concentrations in cell measured by ELISA in each group ( n = 6). (F, G) Western blots showing HPGDS, <t>COX1</t> and COX2 protein levels in OCs treated with A939572. (H) Western blots showing c‐Fos and NFATc1 protein levels in BMDMs treated with varying concentrations of PGD2. (I) Changes in OC‐related markers following RANKL stimulation at different time points, with or without 0.625 μM PGD2 treatment. (J) RT‐qPCR analysis of OC‐related markers in response to different concentrations of PGD2. (K) TRAP staining and F‐actin immunofluorescence staining of OCs treated with or without PGD2; TRAP staining, Scale bars, 100 μm; F‐actin immunofluorescence staining, Scale bars, 100 μm. (L) Quantification of nuclei numbers of TRAP‐positive multinuclear cells ( n = 3). Data are presented as mean ± SD. NS, not significant ( p > 0.05), * p ≤ 0.05, ** p < 0.01, *** p < 0.001. Source numerical and statistical data are provided.
    Anti Cox1 Polyclonal Antibody, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/anti cox1 polyclonal antibody/product/Cell Signaling Technology Inc
    Average 94 stars, based on 1 article reviews
    anti cox1 polyclonal antibody - by Bioz Stars, 2026-05
    94/100 stars
    		  Buy from Supplier
    cox1 amplicon  (Cosmo Genetech Co)
    86
    Cosmo Genetech Co cox1 amplicon
    A939572 inhibits OC differentiation by modulating arachidonic acid metabolism. (A) Integrated transcriptomic and metabolomic analysis. (B) Heatmap of PGD2‐related metabolites. i indicates inhibitor‐treated samples, NC indicates control samples. (C, D) GSEA of arachidonic acid and mineralization‐related metabolites. (E) PGD2 concentrations in cell measured by ELISA in each group ( n = 6). (F, G) Western blots showing HPGDS, <t>COX1</t> and COX2 protein levels in OCs treated with A939572. (H) Western blots showing c‐Fos and NFATc1 protein levels in BMDMs treated with varying concentrations of PGD2. (I) Changes in OC‐related markers following RANKL stimulation at different time points, with or without 0.625 μM PGD2 treatment. (J) RT‐qPCR analysis of OC‐related markers in response to different concentrations of PGD2. (K) TRAP staining and F‐actin immunofluorescence staining of OCs treated with or without PGD2; TRAP staining, Scale bars, 100 μm; F‐actin immunofluorescence staining, Scale bars, 100 μm. (L) Quantification of nuclei numbers of TRAP‐positive multinuclear cells ( n = 3). Data are presented as mean ± SD. NS, not significant ( p > 0.05), * p ≤ 0.05, ** p < 0.01, *** p < 0.001. Source numerical and statistical data are provided.
    Cox1 Amplicon, supplied by Cosmo Genetech Co, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/cox1 amplicon/product/Cosmo Genetech Co
    Average 86 stars, based on 1 article reviews
    cox1 amplicon - by Bioz Stars, 2026-05
    86/100 stars
    		  Buy from Supplier
    cox1  (Cell Signaling Technology Inc)
    95
    Cell Signaling Technology Inc cox1
    A939572 inhibits OC differentiation by modulating arachidonic acid metabolism. (A) Integrated transcriptomic and metabolomic analysis. (B) Heatmap of PGD2‐related metabolites. i indicates inhibitor‐treated samples, NC indicates control samples. (C, D) GSEA of arachidonic acid and mineralization‐related metabolites. (E) PGD2 concentrations in cell measured by ELISA in each group ( n = 6). (F, G) Western blots showing HPGDS, <t>COX1</t> and COX2 protein levels in OCs treated with A939572. (H) Western blots showing c‐Fos and NFATc1 protein levels in BMDMs treated with varying concentrations of PGD2. (I) Changes in OC‐related markers following RANKL stimulation at different time points, with or without 0.625 μM PGD2 treatment. (J) RT‐qPCR analysis of OC‐related markers in response to different concentrations of PGD2. (K) TRAP staining and F‐actin immunofluorescence staining of OCs treated with or without PGD2; TRAP staining, Scale bars, 100 μm; F‐actin immunofluorescence staining, Scale bars, 100 μm. (L) Quantification of nuclei numbers of TRAP‐positive multinuclear cells ( n = 3). Data are presented as mean ± SD. NS, not significant ( p > 0.05), * p ≤ 0.05, ** p < 0.01, *** p < 0.001. Source numerical and statistical data are provided.
    Cox1, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/cox1/product/Cell Signaling Technology Inc
    Average 95 stars, based on 1 article reviews
    cox1 - by Bioz Stars, 2026-05
    95/100 stars
    		  Buy from Supplier
    anti cox 1 antibody  (Cell Signaling Technology Inc)
    94
    Cell Signaling Technology Inc anti cox 1 antibody
    A939572 inhibits OC differentiation by modulating arachidonic acid metabolism. (A) Integrated transcriptomic and metabolomic analysis. (B) Heatmap of PGD2‐related metabolites. i indicates inhibitor‐treated samples, NC indicates control samples. (C, D) GSEA of arachidonic acid and mineralization‐related metabolites. (E) PGD2 concentrations in cell measured by ELISA in each group ( n = 6). (F, G) Western blots showing HPGDS, <t>COX1</t> and COX2 protein levels in OCs treated with A939572. (H) Western blots showing c‐Fos and NFATc1 protein levels in BMDMs treated with varying concentrations of PGD2. (I) Changes in OC‐related markers following RANKL stimulation at different time points, with or without 0.625 μM PGD2 treatment. (J) RT‐qPCR analysis of OC‐related markers in response to different concentrations of PGD2. (K) TRAP staining and F‐actin immunofluorescence staining of OCs treated with or without PGD2; TRAP staining, Scale bars, 100 μm; F‐actin immunofluorescence staining, Scale bars, 100 μm. (L) Quantification of nuclei numbers of TRAP‐positive multinuclear cells ( n = 3). Data are presented as mean ± SD. NS, not significant ( p > 0.05), * p ≤ 0.05, ** p < 0.01, *** p < 0.001. Source numerical and statistical data are provided.
    Anti Cox 1 Antibody, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/anti cox 1 antibody/product/Cell Signaling Technology Inc
    Average 94 stars, based on 1 article reviews
    anti cox 1 antibody - by Bioz Stars, 2026-05
    94/100 stars
    		  Buy from Supplier
    anti cox1  (Proteintech)
    93
    Proteintech anti cox1
    A939572 inhibits OC differentiation by modulating arachidonic acid metabolism. (A) Integrated transcriptomic and metabolomic analysis. (B) Heatmap of PGD2‐related metabolites. i indicates inhibitor‐treated samples, NC indicates control samples. (C, D) GSEA of arachidonic acid and mineralization‐related metabolites. (E) PGD2 concentrations in cell measured by ELISA in each group ( n = 6). (F, G) Western blots showing HPGDS, <t>COX1</t> and COX2 protein levels in OCs treated with A939572. (H) Western blots showing c‐Fos and NFATc1 protein levels in BMDMs treated with varying concentrations of PGD2. (I) Changes in OC‐related markers following RANKL stimulation at different time points, with or without 0.625 μM PGD2 treatment. (J) RT‐qPCR analysis of OC‐related markers in response to different concentrations of PGD2. (K) TRAP staining and F‐actin immunofluorescence staining of OCs treated with or without PGD2; TRAP staining, Scale bars, 100 μm; F‐actin immunofluorescence staining, Scale bars, 100 μm. (L) Quantification of nuclei numbers of TRAP‐positive multinuclear cells ( n = 3). Data are presented as mean ± SD. NS, not significant ( p > 0.05), * p ≤ 0.05, ** p < 0.01, *** p < 0.001. Source numerical and statistical data are provided.
    Anti Cox1, supplied by Proteintech, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/anti cox1/product/Proteintech
    Average 93 stars, based on 1 article reviews
    anti cox1 - by Bioz Stars, 2026-05
    93/100 stars
    		  Buy from Supplier
    d immitis cox1 amplicons  (Macrogen)
    86
    Macrogen d immitis cox1 amplicons
    A939572 inhibits OC differentiation by modulating arachidonic acid metabolism. (A) Integrated transcriptomic and metabolomic analysis. (B) Heatmap of PGD2‐related metabolites. i indicates inhibitor‐treated samples, NC indicates control samples. (C, D) GSEA of arachidonic acid and mineralization‐related metabolites. (E) PGD2 concentrations in cell measured by ELISA in each group ( n = 6). (F, G) Western blots showing HPGDS, <t>COX1</t> and COX2 protein levels in OCs treated with A939572. (H) Western blots showing c‐Fos and NFATc1 protein levels in BMDMs treated with varying concentrations of PGD2. (I) Changes in OC‐related markers following RANKL stimulation at different time points, with or without 0.625 μM PGD2 treatment. (J) RT‐qPCR analysis of OC‐related markers in response to different concentrations of PGD2. (K) TRAP staining and F‐actin immunofluorescence staining of OCs treated with or without PGD2; TRAP staining, Scale bars, 100 μm; F‐actin immunofluorescence staining, Scale bars, 100 μm. (L) Quantification of nuclei numbers of TRAP‐positive multinuclear cells ( n = 3). Data are presented as mean ± SD. NS, not significant ( p > 0.05), * p ≤ 0.05, ** p < 0.01, *** p < 0.001. Source numerical and statistical data are provided.
    D Immitis Cox1 Amplicons, supplied by Macrogen, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/d immitis cox1 amplicons/product/Macrogen
    Average 86 stars, based on 1 article reviews
    d immitis cox1 amplicons - by Bioz Stars, 2026-05
    86/100 stars
    		  Buy from Supplier
    cox1 sequences  (Hasegawa Co Ltd)
    86
    Hasegawa Co Ltd cox1 sequences
    A939572 inhibits OC differentiation by modulating arachidonic acid metabolism. (A) Integrated transcriptomic and metabolomic analysis. (B) Heatmap of PGD2‐related metabolites. i indicates inhibitor‐treated samples, NC indicates control samples. (C, D) GSEA of arachidonic acid and mineralization‐related metabolites. (E) PGD2 concentrations in cell measured by ELISA in each group ( n = 6). (F, G) Western blots showing HPGDS, <t>COX1</t> and COX2 protein levels in OCs treated with A939572. (H) Western blots showing c‐Fos and NFATc1 protein levels in BMDMs treated with varying concentrations of PGD2. (I) Changes in OC‐related markers following RANKL stimulation at different time points, with or without 0.625 μM PGD2 treatment. (J) RT‐qPCR analysis of OC‐related markers in response to different concentrations of PGD2. (K) TRAP staining and F‐actin immunofluorescence staining of OCs treated with or without PGD2; TRAP staining, Scale bars, 100 μm; F‐actin immunofluorescence staining, Scale bars, 100 μm. (L) Quantification of nuclei numbers of TRAP‐positive multinuclear cells ( n = 3). Data are presented as mean ± SD. NS, not significant ( p > 0.05), * p ≤ 0.05, ** p < 0.01, *** p < 0.001. Source numerical and statistical data are provided.
    Cox1 Sequences, supplied by Hasegawa Co Ltd, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/cox1 sequences/product/Hasegawa Co Ltd
    Average 86 stars, based on 1 article reviews
    cox1 sequences - by Bioz Stars, 2026-05
    86/100 stars
    		  Buy from Supplier

    Image Search Results


    A939572 inhibits OC differentiation by modulating arachidonic acid metabolism. (A) Integrated transcriptomic and metabolomic analysis. (B) Heatmap of PGD2‐related metabolites. i indicates inhibitor‐treated samples, NC indicates control samples. (C, D) GSEA of arachidonic acid and mineralization‐related metabolites. (E) PGD2 concentrations in cell measured by ELISA in each group ( n = 6). (F, G) Western blots showing HPGDS, COX1 and COX2 protein levels in OCs treated with A939572. (H) Western blots showing c‐Fos and NFATc1 protein levels in BMDMs treated with varying concentrations of PGD2. (I) Changes in OC‐related markers following RANKL stimulation at different time points, with or without 0.625 μM PGD2 treatment. (J) RT‐qPCR analysis of OC‐related markers in response to different concentrations of PGD2. (K) TRAP staining and F‐actin immunofluorescence staining of OCs treated with or without PGD2; TRAP staining, Scale bars, 100 μm; F‐actin immunofluorescence staining, Scale bars, 100 μm. (L) Quantification of nuclei numbers of TRAP‐positive multinuclear cells ( n = 3). Data are presented as mean ± SD. NS, not significant ( p > 0.05), * p ≤ 0.05, ** p < 0.01, *** p < 0.001. Source numerical and statistical data are provided.

    Journal: The FASEB Journal

    Article Title: SCD1 Regulates Osteoclast Differentiation by Modulating Arachidonic Acid Metabolism and Mitochondrial Homeostasis

    doi: 10.1096/fj.202600672R

    Figure Lengend Snippet: A939572 inhibits OC differentiation by modulating arachidonic acid metabolism. (A) Integrated transcriptomic and metabolomic analysis. (B) Heatmap of PGD2‐related metabolites. i indicates inhibitor‐treated samples, NC indicates control samples. (C, D) GSEA of arachidonic acid and mineralization‐related metabolites. (E) PGD2 concentrations in cell measured by ELISA in each group ( n = 6). (F, G) Western blots showing HPGDS, COX1 and COX2 protein levels in OCs treated with A939572. (H) Western blots showing c‐Fos and NFATc1 protein levels in BMDMs treated with varying concentrations of PGD2. (I) Changes in OC‐related markers following RANKL stimulation at different time points, with or without 0.625 μM PGD2 treatment. (J) RT‐qPCR analysis of OC‐related markers in response to different concentrations of PGD2. (K) TRAP staining and F‐actin immunofluorescence staining of OCs treated with or without PGD2; TRAP staining, Scale bars, 100 μm; F‐actin immunofluorescence staining, Scale bars, 100 μm. (L) Quantification of nuclei numbers of TRAP‐positive multinuclear cells ( n = 3). Data are presented as mean ± SD. NS, not significant ( p > 0.05), * p ≤ 0.05, ** p < 0.01, *** p < 0.001. Source numerical and statistical data are provided.

    Article Snippet: Antibodies against the following targets were used: COX1 (ET1610‐98, HUABIO), COX2 (ET1610‐23, HUABIO), HPGDS (ER60724, HUABIO), TOM20 (ET1609‐25, HUABIO), Tartrate Resistant Acid Phosphatase (TRAP; ab191406, Abcam), SCD1 (ab236868, Abcam), SP7 (ab209484, Abcam), Runx2 (ab133261, Abcam), p65 (8242, Cell Signaling Technology), phospho‐p65 (p‐p65; 3033, Cell Signaling Technology), p38 (9212, Cell Signaling Technology), phospho‐p38 (p‐p38; 4511, Cell Signaling Technology), JNK (9252, Cell Signaling Technology), phospho‐JNK (p‐JNK; 9255, Cell Signaling Technology), Erk (5013, Cell Signaling Technology), phospho‐Erk (p‐Erk; 4370, Cell Signaling Technology), Flag (14793S, Cell Signaling Technology), c‐Fos (31 254, Cell Signaling Technology), NDUFS4 (15849‐1‐APM, Proteintech), β‐actin (66009‐1‐Ig, Proteintech), NFATc1 (sc‐7294, Santa Cruz Biotechnology).

    Techniques: Metabolomic, Control, Enzyme-linked Immunosorbent Assay, Western Blot, Quantitative RT-PCR, Staining, Immunofluorescence